Document Detail

KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy.
MedLine Citation:
PMID:  20854963     Owner:  NLM     Status:  MEDLINE    
Evidence from multiple large prospective studies suggests that a common polymorphism that encodes an arginine (Arg)-to-tryptophan substitution at position 719 in the KIF6 gene is associated with coronary heart disease (CHD) and reduction in coronary events from statin therapy. Carriers of the 719Arg allele were at greater risk for primary and secondary CHD events, and statin therapy significantly reduced coronary events in 719Arg carriers but not in noncarriers. The number needed to treat to prevent a single CHD event ranged from 10 to 20 for 719Arg carriers, compared to >80 for noncarriers in the Cholesterol and Recurrent Events (CARE) study, the West of Scotland Coronary Prevention Study (WOSCOPS), the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI22) study. In conclusion, assessment of 719Arg carrier status holds promise for stratification of coronary event risk and for selection of optimal therapy in primary and secondary CHD prevention.
Yonghong Li; Olga A Iakoubova; Dov Shiffman; James J Devlin; James S Forrester; H Robert Superko
Related Documents :
16534223 - Influence of different lipid-lowering strategies on plaque volume and plaque compositio...
25222913 - Hydrogen sulfide alleviates myocardial collagen remodeling in association with inhibiti...
23739933 - Beneficial effects of hyperosmotic perfusion in the myocardium after ischemia/reperfusi...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-08-11
Journal Detail:
Title:  The American journal of cardiology     Volume:  106     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-21     Completed Date:  2010-10-26     Revised Date:  2010-12-17    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  994-8     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Celera, Alameda, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Disease / drug therapy,  genetics*,  prevention & control
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Kinesin / genetics*
Polymorphism, Genetic*
Predictive Value of Tests
Primary Prevention
Risk Assessment
Risk Factors
Secondary Prevention
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; EC 3.6.1.-/KIF6 protein, human; EC 3.6.1.-/Kinesin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Red cell distribution width and risk of coronary heart disease events.
Next Document:  Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular ...